Table 1.
Next‐generation sequencing‐based tumor‐profiling multiplex gene panels
| Test | Number of genes tested | Tumor sample | Non‐tumor sample | FDA approval | Companion diagnostic indications linked to gene alterations |
|---|---|---|---|---|---|
| Oncomine Dx target test | 23 | Tissue DNA/RNA | Not used | Yes | Lung cancer: EGFR, ROS1, and BRAF |
| FoundationOne CDx | 324 | Tissue DNA | Not used | Yes |
Lung cancer: EGFR, ALK, and BRAF
Melanoma: BRAF Breast cancer: HER2 (ERBB2) Colorectal cancer: KRAS and NRAS Ovarian cancer: BRCA1 and BRCA2 |
| MSK‐IMPACT | 468 | Tissue DNA | Peripheral blood | Yes | Unknown |
| Guardant360 | 73 | Cell‐free DNA | Not used | Unknown | Unknown |
| NCC oncopanel | 114 | Tissue DNA | Peripheral blood | Unknown | Unknown |
| Oncoprime | 215 | Tissue DNA | Not used | Unknown | Unknown |